



|                  |                                                                                                                                                                                                            |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Title            | Pre-operative left atrial size and functions are predictors of left atrial reverse remodelling after mitral valvuloplasty for myxomatous mitral valve disease in dogs                                      |
| Author(s)        | Kawamoto, S.; Nakamura, K.; Mori, T. et al.                                                                                                                                                                |
| Citation         | Journal of veterinary cardiology, 57, 47-57<br><a href="https://doi.org/10.1016/j.jvc.2024.10.007">https://doi.org/10.1016/j.jvc.2024.10.007</a>                                                           |
| Issue Date       | 2025-02                                                                                                                                                                                                    |
| Doc URL          | <a href="https://hdl.handle.net/2115/97401">https://hdl.handle.net/2115/97401</a>                                                                                                                          |
| Rights           | © 2025. This manuscript version is made available under the CC-BY-NC-ND 4.0 license<br><a href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</a> |
| Rights(URL)      | <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</a>                                                                                        |
| Type             | journal article                                                                                                                                                                                            |
| File Information | Manuscript File3.pdf                                                                                                                                                                                       |



**Preoperative left atrial size and functions are predictors of left atrial reverse remodelling after mitral valvuloplasty for myxomatous mitral valve disease in dogs**

Short title: Predictors of left atrial size after mitral valvuloplasty in dogs

Sei Kawamoto<sup>a,b,c</sup>, DVM, Kensuke Nakamura<sup>a,\*</sup>, PhD, Takuya Mori<sup>b</sup>, DVM, Tomoki Wada<sup>b</sup>, DVM, Akira Fujiwara<sup>b</sup>, DVM, Mitsuyoshi Takiguchi<sup>a</sup>, PhD

<sup>a</sup> Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, N18 W9, Sapporo, Hokkaido 060-0818, Japan.

<sup>b</sup> JACCT Japan Animal Cardiovascular Care Team, 3-15-27 Hishie, Higashiosaka, Osaka 578-0984, Japan.

<sup>c</sup> Matsubara Animal Hospital, 2-1-7 Taijo, Matsubara, Osaka 580-0044, Japan.

\* Corresponding author:

Kensuke Nakamura. Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, N18 W9, Sapporo, Hokkaido 060-0818, Japan.

E-mail address: [nken@vetmed.hokudai.ac.jp](mailto:nken@vetmed.hokudai.ac.jp)

## **Abstract**

**Objectives:** The objective of this study was to determine alterations in left atrial size, function, and determinants of left atrial reverse remodelling (LARR) after mitral valvuloplasty (MVP) in dogs with myxomatous mitral valve disease (MMVD).

**Animals:** Thirty-seven dogs undergoing MVP.

**Materials and Methods:** Echocardiographic parameters, including left atrial (LA) strain, were evaluated at baseline, during the early postoperative period (within two weeks), and at one and three months postoperatively. Patients were divided into two groups based on the attainment of LARR, defined as a left atrial to aortic root ratio (LA:Ao) < 1.6 at three months. The predictors of LARR were analysed using univariate logistic regression analysis.

**Results:** LA:Ao significantly decreased in the early postoperative period (median 1.68; lower and upper quartile 1.54–1.92) compared to baseline (2.41; 2.00–2.80), with a further significant reduction observed at three months (1.46; 1.34–1.63). LARR was achieved in 27 (73%) patients. Baseline LA:Ao was higher, and peak atrial longitudinal strain (PALS) and peak atrial construction strain (PACS) were lower in the non-LARR group than in the LARR group. Among the baseline parameters, PACS was the strongest predictor of LARR (area under the curve, 0.837).

Conclusions: Following MVP, the LA size decreased in the early postoperative period and continued to decrease over three months of follow-up. A low PACS score was the most reliable predictor of inadequate LARR. Further studies are necessary to determine the relationship between LARR, prognosis, and the optimal timing for surgical intervention.

#### **Keywords**

Mitral regurgitation; Left atrial strain; Speckle tracking echocardiography; Booster pump function; Reservoir function

## 47    **Abbreviations**

|       |                                                      |
|-------|------------------------------------------------------|
| 2DSTE | two-dimensional speckle tracking<br>echocardiography |
| LA    | left atrium                                          |
| LARR  | left atrial reverse remodelling                      |
| LA:Ao | left atrial to aortic root ratio                     |
| LV    | left ventricle                                       |
| MMVD  | myxomatous mitral valve disease                      |
| MR    | mitral regurgitation                                 |
| MVP   | mitral valvuloplasty                                 |
| PACS  | peak atrial contraction strain                       |
| PALS  | peak atrial longitudinal strain                      |

48

49

## 50    **Introduction**

51    Myxomatous Mitral Valve Disease (MMVD) is the most common cardiac disease  
52    acquired in canines [1,2]. Mitral regurgitation (MR), resulting from myxomatous valve  
53    degeneration, induces volume overload in the left heart. Volume overload in the left

atrium (LA) initiates a remodelling process, marked by the expansion of the LA chamber coupled with a corresponding decrease in its function. Two-dimensional echocardiographic parameters of the LA, including the left atrial-to-aortic root ratio (LA:Ao) and LA maximal volume, have been established as prognostic markers for canines with MMVD [3-5]. The LA plays a critical role in filling the left ventricle (LV) and maintaining the optimal cardiac output by functioning as a reservoir, conduit, and booster pump. During systole and isovolumic relaxation, the LA acts as a reservoir, receiving blood from the pulmonary veins, and storing energy in the form of pressure. In early diastole, it serves as a conduit, facilitating blood flow from the LA to the LV via a pressure gradient and enabling passive blood flow from the pulmonary veins into the LV. In late diastole, the LA functions as a booster pump and its active contraction increases the LV stroke volume by approximately 20–30% in healthy individuals [6,7]. LA function can be assessed by volumetric analysis and strain analysis using two-dimensional speckle tracking echocardiography (2DSTE) [8]. The previous studies have shown that indices of reservoir and booster pump function assessed by LA strain are more indicative of the prognosis of MMVD in canines than LA size [9,10].

After Mitral Valvuloplasty (MVP) in human patients with MR, the reduction in volume load owing to improved MR leads to an immediate decrease in LA size and

pressure [11,12]. Furthermore, a decrease in LA wall stress contributes to improvements in LA fibrosis and myocardial remodelling, resulting in further improvements in LA size and function [13]. These postoperative structural and functional alterations of the LA are termed left atrial reverse remodelling (LARR). Several studies indicate that 16–34% patients experience inadequate LARR following mitral valve surgery [11,14,15]. Inadequate LARR is associated with poor outcomes, including a higher risk of stroke, atrial fibrillation, and shortened survival [15]. Preoperative indices of LA volume and function have proven to be predictors of LARR, underscoring the need for preoperative assessment of LA structure and function in patients with MR. In dogs, a decrease in LA size is observed in many cases after MVP for MMVD; however, inadequate LARR is also observed in some cases [16,17,18]. Nonetheless, studies focusing on LA function in dogs undergoing MVP are scarce, and clinical and echocardiographic indices that predict LARR remain undefined.

The primary objective of this study was to determine changes in LA size and function after MVP in dogs with MMVD. The secondary aim was to identify predictors of postoperative LARR. We hypothesised that preoperative LA strain indices, as determined using 2DSTE, could be predictors of LARR.

## **Animals, materials, and methods**

### **Animals**

Dogs that underwent MVP for severe chronic MR associated with MMVD by the Japan Animal Cardiovascular Care Team between November 2019 and August 2020 were included in this study. All dogs in this study underwent complete physical and echocardiographic examinations of adequate quality for 2DSTE analysis, ensuring no deficits during the follow-up period. Data concerning age, breed, sex, weight, echocardiographic indices, and treatment were collected from medical records. Dogs with early postoperative death, postoperative ischaemic myocardial damage, residual moderate or greater postoperative MR, or persistent atrial fibrillation, both pre- and post-surgery, were excluded. Ischemic myocardial injury was identified through a focal reduction in myocardial motility, accompanied by postoperative ST-segment elevation and progressive thinning of the myocardium over time. The severity of residual postoperative MR was determined by calculating the proportion of the regurgitant jet area to the left atrial area using color Doppler, with a ratio of 20% or more considered moderate or greater regurgitation.

### **Surgery**

Surgery was performed through left fifth intercostal thoracotomy. Hypothermic

108 cardiopulmonary bypass was established via cannulation of the left external jugular  
109 vein and left common carotid artery. Cardiac arrest was achieved by occluding the  
110 aorta proximal to the brachiocephalic artery using aortic clamping forceps and  
111 administering cardioplegia through a cannula positioned at the aortic root. Following  
112 cardiac arrest, the LA was incised to access the mitral valve. Artificial chordae  
113 tendineae reconstruction and mitral annuloplasty were performed in all cases,  
114 including resection of excess subvalvular tissue, resection of ruptured chordae  
115 tendineae, and cleft closure of the valve leaflet as necessary. The duration of  
116 cardiopulmonary bypass and aortic cross-clamp was documented.

## 117 **Echocardiography**

118 Echocardiographic examinations were performed utilizing a standard  
119 echocardiographic systems<sup>d</sup> equipped with a 2.9/5.8 MHz sector probe transducer.  
120 These assessments were performed at baseline, in the early postoperative period  
121 (within two weeks), and at one and three months postoperatively. All examinations  
122 were performed with the patients in a nonsedated state and manually positioned in  
123 both the right and left lateral recumbent positions on the examination table. The LA  
124 size was evaluated using the LA:Ao at the level of the aortic valve in the right  
125 parasternal short-axis cross-sectional view in early ventricular diastole using the first

frame after aortic ejection [19]. Left ventricular end-diastolic and end-systolic diameters were measured using M-mode images at the level of the chordae tendineae in the right parasternal short-axis view. Left ventricular fractional shortening (FS) was recorded, and the end-diastolic and end-systolic LV internal diameters were standardised by body weight using the following formulas:  $LVIDDN = LV \text{ end-diastolic internal diameter} / (\text{body weight})^{0.294}$ ,  $LVIDSN = LV \text{ end-systolic internal diameter} / (\text{body weight})^{0.315}$ . The criteria for LA and LV enlargement were  $LA:Ao > 1.6$  and  $LVIDDN > 1.7$  according to ACVIM guidelines [20]. Left ventricular inflow patterns were analysed using pulsed-wave Doppler to measure the maximum early diastolic inflow velocity (E), maximum late diastolic inflow velocity (A), and E:A from the apical four-chamber view. Left and right ventricular outflow tract blood flow velocities were also assessed using pulsed-wave Doppler from the apical five-chamber view and right parasternal short-axis view at the pulmonary artery valve level, respectively.

### **Speckle tracking echocardiography**

Left atrial strain measurements were conducted offline by a sole examiner (S. K.) using vendor-independent 2D Speckle Tracking software<sup>e</sup>. The analysis was performed offline from 2D DICOM videos capturing three consecutive heartbeats. The LA endocardial border was traced as the region of interest in the end-systolic phase in the

LA-focused apical four-chamber view, ensuring the exclusion of the left auricle and pulmonary vein. Left atrial strain measurement throughout the cardiac cycle was set to start at the beginning of the QRS complex, and a global LA strain-time curve was generated. The strain at the end of the LA systole was set as the zero-reference value. Left atrial peak strain measured just before the mitral valve opening was defined as peak atrial longitudinal strain (PALS), and LA strain measured just before atrial contraction (coinciding with the onset of the P-wave on electrocardiography) was identified as peak atrial contraction strain (PACS) (Figure 1). All LA strain measurements were averaged over three consecutive cardiac cycles.

### **Statistical analyses**

Measurements are presented as median and lower and upper quartile. Multiple comparisons of continuous variables at baseline, early postoperative period, one month, and three months were performed using the Steel-Dwass test. The relationships between different measurements were assessed using Spearman's correlation analysis. Simple linear logistic regression analyses were used to predict LA:Ao at three months after MVP from preoperative left atrial size and functional indices. Left atrial reverse remodelling was defined as achieving LA:Ao < 1.6 at three months after MVP, and the cases were divided into two groups (LARR and non-LARR

groups). Variables were compared by The Kruskal-Wallis test for continuous variables and Fisher's exact test for categorical variables between the two groups. Predictors of LARR were assessed using binary logistic regression analysis. Echocardiographic variables with  $P < 0.05$  in univariate analyses were included in the multivariate analysis, which was performed using a stepwise forward selection method with a threshold of  $P < 0.1$  for variable inclusion. Receiver-operating characteristic curves and the area under each receiver-operating characteristic curves were calculated to assess the accuracy of each measure at baseline in discriminating between the LARR and non-LARR groups. Statistical analyses were performed using commercial software<sup>f</sup>. A two-sided  $P$ -value  $< 0.05$  was considered significant.

## Result

Mitral Valvuloplasty was performed in 61 patients with MMVD between November 2019 and August 2020. Of the 61 cases, 37 were enrolled for 2DSTE analysis, while six cases were excluded for poor echocardiographic window, six for death due to postoperative complications, six lost to follow-up, three for residual MR at one or three months, two for pre- and postoperative arrhythmias, and one for severe postoperative LV dysfunction. The 37 patients included 14 in stage B2, 14 in stage C,

and nine in stage D. The most commonly represented breeds were Chihuahua (n = 19), followed by mixed breed (n = 7), Toy Poodle (n = 4), Maltese (n = 2), Cavalier King Charles Spaniel (n = 2), Miniature Dachshund (n = 2), and Miniature Schnauzer (n = 1). Dogs were treated with pimobendan (n = 36), ACE inhibitors (n = 29), torsemide (n = 29), amlodipine (n=28), spironolactone (n = 20), furosemide (n = 7), hydrochlorothiazide (n = 2), and tolvaptan (n = 2). Table 1 shows the demographic data, surgical dates, and echocardiographic characteristics of the patients.

The echocardiographic indices from baseline to three months follow-up are presented in Table 2. Left atrial-to-aortic root ratio began to decrease in the early postoperative period and continued to decrease for three months (Figure 2A). Peak atrial longitudinal strain also decreased in the early postoperative period but tended to increase at three months (Figure 2B). Peak atrial construction strain showed a non-significant tendency to decrease in the early postoperative period, but then reversed and increased at three months (Figure 2C).

The correlations between LA size and function at three months and baseline echocardiographic indices are presented in Table 3. Left atrial-to-aortic root ratio at three months demonstrated a correlation with baseline LA:Ao ( $\rho = 0.485$ ,  $P = 0.002$ ), PALS ( $\rho = -0.543$ ,  $P < 0.001$ ) and PACS ( $\rho = -0.546$ ,  $P < 0.001$ ) respectively (Figure

3). Peak atrial longitudinal strain at three months correlated with baseline PALS ( $\rho = 0.504$ ,  $P = 0.002$ ) and PACS ( $\rho = 0.514$ ,  $P = 0.001$ ). Peak atrial construction strain at three months was correlated with baseline PALS ( $\rho = 0.563$ ,  $P < 0.001$ ), PACS ( $\rho = 0.529$ ,  $P < 0.001$ ). No correlation was found between the duration from surgery to the early postoperative period and LA:Ao ( $\rho < 0.001$ ,  $P = 0.998$ ), PALS ( $\rho = 0.127$ ,  $P = 0.455$ ), or PACS ( $\rho = 0.108$ ,  $P = 0.536$ ) in the early postoperative period. Predictive equations for LA:Ao at three months after MVP derived from indices of preoperative left atrial size and function indices are presented in Table 4.

The clinical and echocardiographic indices of the LARR and non-LARR groups are presented in Table 5. Left atrial reverse remodelling was achieved in 73% (27/37) of cases at three months. Age, sex, weight, and history of pulmonary oedema were not significantly different between the two groups. Baseline LA:Ao was higher, and PALS and PACS were lower in the non-LARR group than in the LARR group (Figure 4). Receiver-operating characteristic curves analysis showed that the baseline PACS had the highest area under the curve for discriminating between the LARR and non-LARR groups (Table 6).

Univariate logistic regression analysis showed that LA:Ao, PALS, and PACS were significantly related to LARR at three months after MVP. Subsequently,

multivariate logistic regression analysis identified PACS as the only independent correlate ( $P = 0.008$ , odds ratio 0.760 [95% Confidence Interval 0.595–0.970]) (Table 7).

## Discussion

In the present study, 73% of the dogs with MMVD achieved LARR three months after MVP, and preoperative LA size and function were predictors.

In humans, inadequate LARR has been identified as a poor prognostic factor for atrial fibrillation, stroke, and all-cause mortality [15,21]. In humans, factors associated with LARR after mitral valve surgery include the preoperative LA volume index [22], preoperative reservoir function index [23], postoperative mitral stenosis, and postoperative MR severity [15]. In the present study, no patient developed post-surgical mitral stenosis, and patients with postoperative moderate MR were excluded. This study implies that the preoperative LA size and function indices, particularly the booster pump function index, are valuable in identifying cases of inadequate LARR and LA size at three months after MVP.

Reduced LA function has been identified as a better prognostic factor than LA size on primary human MR, suggesting that it is an important factor in assessing the

suitability of surgical intervention [24-26]. Previous studies also demonstrated that LA function is more relevant than LA size to the severity and prognosis of MMVD in dogs than LA size [9,10]. Left atrial size is an important indicator of MR severity, whereas LA enlargement is a compensatory response to prevent MR-induced increases in LA pressure. In other words, in a highly compensated LA, LA pressure may remain within normal limits despite severe LA enlargement [27]. However, severe, long-lasting volume overload in the LA results in interstitial fibrosis, endocardial thickening, chronic inflammation, myocyte hypertrophy, and reduced matrix protease expression [28,29], ultimately leading to reduced LA function and increased LA pressure. Therefore, solely evaluating the LA size is inadequate for determining the severity of MR, and the assessment of LA function is crucial.

Left atrial reservoir function is influenced by LV contractility and LA compliance. In MMVD, LV contractility often increases in response to volume loading according to Frank-Starling's law [30]. Thus, in dogs with MMVD, decreased reservoir function is likely influenced by decreased LA compliance. It has been reported that patients with MR with impaired reservoir function have more LA fibrosis and endocardial thickening [31], and the fact that LARR was better in dogs with preserved reservoir function in the present study suggests that fibrosis is less prevalent and reversible in these dogs.

Booster pump function is influenced by preload, afterload, and intrinsic LA contractility. In chronic MR, booster pump function is increased or maintained in response to an increased preload, following the Frank–Starling law. However, in advanced MR, booster pump function is diminished due to excessive preload (beyond the optimal Frank-Starling curve), afterload mismatch resulting from increased LV end-diastolic pressure, and reduced intrinsic LA contractility resulting from fibrosis and other cellular damage [10,32]. Patients with impaired booster pump function are considered to have more advanced LA damage than those with impaired reservoir function [32-36]. The findings of the present study indicate that the booster pump function index is more effective than the reservoir function index in identifying severe cases characterised by irreversible and extensive changes in the LA.

An additional key finding of this study was the difference in post-operative changes between LA size and functional indices. In the present study, the LA size decreased after MVP, with a further significant reduction at three months follow-up. Such gradual changes were also observed in humans [15, 22]. The main reason for the early reduction in LA size could be the improvement in volume overload associated with the disappearance or reduction of MR. On the other hand, PALS and PACS declined after surgery, but then reversed to improve. The postoperative reduction in

PALS and PACS could be attributed to the reduced preload with improved MR. Indeed, previous studies showed that PALS and PACS tended to be higher in MMVD stage B1 cases (median PALS, 32.7%; median PACS, 19.1%) than in normal small dogs (median PALS, 25.2%; median PACS, 14.9%), and the presence of MR may increase PACS and PALS [10,37]. In addition, the restriction of left atrial movement around the annulus due to annuloplasty, along with surgical manipulations such as LA incision and suturing, may have contributed to the decline in left atrial function in the early postoperative period. Thus, this study demonstrates that morphological and functional remodelling occur differently.

In humans, postoperative LA function is important because prolonged LA dysfunction may be linked to poor prognostic outcomes, including the onset of postoperative atrial fibrillation after coronary artery bypass graft surgery [38]. In the current study, baseline PALS and PACS were correlated with PALS and PACS at three months, while the baseline LA:Ao was not correlated. This indicates that the preoperative LA function indices are associated with postoperative functional reverse remodelling.

## **Limitation**

This study had several limitations. First, it involved a small cohort consisting

288 primarily of small dogs with a median weight of 3.8 kg. Additional research is needed  
289 to investigate LARR in medium and large dogs across diverse case groups. Secondly,  
290 this study focused solely on predicting early postoperative LARR. While this finding  
291 suggests that early surgical intervention with preserved LA function is beneficial for  
292 LARR, the long-term course of LARR and its correlation with the long-term prognosis  
293 require extensive research. Third, this study did not evaluate the prognostic value of  
294 an LA:Ao < 1.6 at three months postoperatively. The cutoff value for LARR should be  
295 determined in future research based on its relationship with prognosis. Fourth, The  
296 influence of the duration of mitral valve insufficiency on LARR was not assessed in this  
297 study. Accurately determining the duration of the time in all cases was challenging due  
298 to the nature of being a referral hospital. Fifth, left atrial size was evaluated exclusively  
299 using the LA:Ao due to retrospective nature of this study. Evaluating postoperative  
300 changes in left atrial size using left atrial diameter or volumetric methods may enable  
301 a more precise assessment of LARR. Finally, although 2DSTE has the advantage of  
302 angle independence, it requires high-quality echocardiographic movies that completely  
303 delineate the LA endocardium throughout the cardiac cycle. In this study, 10% (n = 6)  
304 of the cases yielded echocardiographic images that were inadequate for 2DSTE  
305 analysis. However, this may be challenging to implement in all clinical settings because  
306 of the need for high-quality image data for analysis.

307

## 308 **Conclusion**

309 Following MVP, LA size decreased in the early postoperative period and continued to  
310 diminish over a three months follow-up. A low PACS score proved to be the most  
311 reliable predictor of insufficient LARR. Further studies are required to determine the  
312 relationship between LARR, prognosis, and the optimal timing for surgical intervention.

313

## 314 **Funding**

315 This study was partially supported by the Grants-in-Aid for Scientific Research from  
316 the Japanese Society for the Promotion of Science (Nos. 23K05548 and 19K06422).

317

## 318 **Conflict of Interest Statement**

319 The authors do not have any conflicts of interest to disclose.

320

321 **Footnotes**

322 a. Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical  
323 Sciences, Graduate School of Veterinary Medicine, Hokkaido University, N18 W9,  
324 Sapporo, Hokkaido 060-0818, Japan

325 b. JACCT Japan Animal Cardiovascular Care Team, 3-15-27 Hishie, Higashiosaka-shi,  
326 Osaka-fu 578-0984, Japan

327 c. Matsubara Animal Hospital, 2-1-7 Taijo, Matsubara-shi, Osaka-fu 580-0044, Japan

328 d. Vivid E95, GE Health Care, Tokyo, Japan

329 e. 2D Cardiac Performance Analysis, TomTec Imaging System, Unterschleissheim,  
330 Germany

331 f. JMP version 13.0, SAS Institute Inc., Cary, NC, USA

332

## Reference

- [1] Beardow AW, Buchanan JW. Chronic mitral valve disease in cavalier King Charles spaniels: 95 cases (1987-1991). *J Am Vet Med Assoc* 1993;203:1023-9.
- [2] Serfass P, Chetboul V, Sampedrano CC, Nicolle A, Benalloul T, Laforge H, Gau C, Hébert C, Pouchelon JL, Tissier R. Retrospective study of 942 small-sized dogs: Prevalence of left apical systolic heart murmur and left-sided heart failure, critical effects of breed and sex. *J Vet Cardiol* 2006;8:11-8.
- [3] Borgarelli M, Savarino P, Crosara S, Santilli RA, Chiavegato D, Poggi M, Bellino C, La Rosa G, Zanatta R, Haggstrom J, Tarducci A. Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. *J Vet Intern Med* 2008;22:120-8.
- [4] Sargent J, Muzzi R, Mukherjee R, Somaratne S, Schranz K, Stephenson H, Connolly D, Brodbelt D, Fuentes VL. Echocardiographic predictors of survival in dogs with myxomatous mitral valve disease. *J Vet Cardiol* 2015;17:1-12.
- [5] Baron Toaldo M, Romito G, Guglielmini C, Diana A, Pelle NG, Contiero B, Cipone M. Prognostic value of echocardiographic indices of left atrial morphology and function in dogs with myxomatous mitral valve disease. *J Vet Intern Med* 2018;32:914-21.

- 350 [6] Hoit BD, Shao Y, Gabel M, Walsh RA. In vivo assessment of left atrial contractile  
351 performance in normal and pathological conditions using a time-varying elastance  
352 model. *Circulation* 1994;89:1829-38.
- 353 [7] Rosca M, Lancellotti P, Popescu BA, Piérard LA. Left atrial function:  
354 pathophysiology, echocardiographic assessment, and clinical applications. *Heart*  
355 2011;97:1982-9.
- 356 [8] Thomas L, Marwick TH, Popescu BA, Donal E, Badano LP. Left Atrial Structure and  
357 Function, and Left Ventricular Diastolic Dysfunction: JACC State-of-the-Art Review. *J*  
358 *Am Coll Cardiol* 2019;73:1961-77.
- 359 [9] Nakamura K, Osuga T, Morishita K, Suzuki S, Morita T, Yokoyama N, Ohta H,  
360 Yamasaki M, Takiguchi M. Prognostic value of left atrial function in dogs with chronic  
361 mitral valvular heart disease. *J Vet Intern Med* 2014;28:1746-52.
- 362 [10] Nakamura K, Kawamoto S, Osuga T, Morita T, Sasaki N, Morishita K, Ohta H,  
363 Takiguchi M. Left atrial strain at different stages of myxomatous mitral valve disease in  
364 dogs. *J Vet Intern Med* 2017;31:316-25.
- 365 [11] Antonini-Canterin F, Beladan CC, Popescu BA, Ginghina C, Popescu AC, Piazza  
366 R, Leiballi E, Zingone B, Nicolosi GL. Left atrial remodelling early after mitral valve  
367 repair for degenerative mitral regurgitation. *Heart* 2008;94:759-64.

368 [12] Hyllén S, Nozohoor S, Meurling C, Wierup P, Sjögren J. Pulmonary capillary  
 369 wedge pressure and natriuretic peptide levels in patients with sinus rhythm and severe  
 370 left atrial enlargement following mitral valve surgery: early and late changes. *Heart  
 371 Lung Vessel* 2015;7:7-17.

372 [13] Marsan NA, Maffessanti F, Tamborini G, Gripari P, Caiani E, Fusini L, Muratori M,  
 373 Zanobini M, Alamanni F, Pepi M. Left atrial reverse remodeling and functional  
 374 improvement after mitral valve repair in degenerative mitral regurgitation: a real-time  
 375 3-dimensional echocardiography study. *Am Heart J* 2011;161:314-21.

376 [14] Chipeta P, Shim CY, Hong GR, Kim D, Cho IJ, Lee S, Chang HJ, Chang BC, Ha  
 377 JW, Chung N. Time course of left atrial reverse remodelling after mitral valve surgery  
 378 and the impact of left ventricular global longitudinal strain in patients with chronic  
 379 severe mitral regurgitation. *Interact Cardiovasc Thorac Surg* 2016;23:876-82.

380 [15] Stassen J, van Wijngaarden AL, Wu HW, Palmen M, Tomsic A, Delgado V, Bax JJ,  
 381 Marsan NA. Left atrial remodelling after mitral valve repair for primary mitral  
 382 regurgitation: Evolution over time and prognostic significance. *J Cardiovasc Dev Dis*  
 383 2022;9:230.

384 [16] Uechi M, Mizukoshi T, Mizuno T, Mizuno M, Harada K, Ebisawa T, Takeuchi J,  
 385 Sawada T, Uchida S, Shinoda A, Kasuya A, Endo M, Nishida M, Kono S, Fujiwara M,

386 Nakamura T. Mitral valve repair under cardiopulmonary bypass in small-breed dogs:  
 387 48 cases (2006-2009). J Am Vet Med Assoc 2012;240:1194-201.

388 [17] Matsuura K, Yoshida T, Yamada S, Aboshi Y, Yotsuida H, Yaginuma Y, Hasegawa  
 389 M. The outcome of surgical mitral valve repair with loop-in-loop technique in dogs with  
 390 different stage myxomatous mitral valve disease. J Vet Cardiol 2022;42:74-82.

391 [18] Pennington C, Kurosawa TA, Navarro-Cubas X, Bristow P. Use of the Functional  
 392 Evaluation of Cardiac Health questionnaire to assess health-related quality of life  
 393 before and after mitral valve repair in dogs with myxomatous mitral valve disease. J  
 394 Am Vet Med Assoc 2022;260:1806-12.

395 [19] Hansson K, Häggström J, Kvart C, Lord P. Left atrial to aortic root indices using  
 396 two-dimensional and M-mode echocardiography in cavalier King Charles spaniels with  
 397 and without left atrial enlargement. Vet Radiol Ultrasound 2002;43:568-75.

398 [20] Keene BW, Atkins CE, Bonagura JD, Fox PR, Häggström J, Fuentes VL, Oyama  
 399 MA, Rush JE, Stepien R, Uechi M. ACVIM consensus guidelines for the diagnosis and  
 400 treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med 2019;33:1127-  
 401 40.

402 [21] Kang MK, Joung B, Shim CY, Cho IJ, Yang WI, Moon J, Jang Y, Chung N, Chang  
 403 BC, Ha JW. Postoperative left atrial volume index is a predictor of the occurrence of

404 permanent atrial fibrillation after mitral valve surgery in patients who undergo mitral  
 405 valve surgery. *Cardiovasc Ultrasound* 2018;16:5.

406 [22] Balachandran P, Schaff HV, Lahr BD, Nguyen A, Daly RC, Maltais S, Pislaru SV,  
 407 Dearani JA. Preoperative left atrial volume index is associated with postoperative  
 408 outcomes in mitral valve repair for chronic mitral regurgitation. *J Thorac Cardiovasc*  
 409 *Surg* 2020;160:661-72.

410 [23] Candan O, Ozdemir N, Aung SM, Hatipoglu S, Karabay CY, Guler A, Gecmen C,  
 411 Dogan C, Omaygenc O, Bakal RB. Atrial longitudinal strain parameters predict left  
 412 atrial reverse remodeling after mitral valve surgery: A speckle tracking  
 413 echocardiography study. *Int J Cardiovasc Imaging* 2014;30:1049-56.

414 [24] Cameli M, Pastore MC, Righini FM, Mandoli GE, D'Ascenzi F, Lisi M, Nistor D,  
 415 Sparla S, Curci V, Di Tommaso C, Marino F, Stricagnoli M, Mondillo S. Prognostic value  
 416 of left atrial strain in patients with moderate asymptomatic mitral regurgitation. *Int J*  
 417 *Cardiovasc Imaging* 2019;35:1597-604.

418 [25] Yang LT, Liu YW, Shih JY, Li YH, Tsai LM, Luo CY, Tsai WC. Predictive value of  
 419 left atrial deformation on prognosis in severe primary mitral regurgitation. *J Am Soc*  
 420 *Echocardiogr* 2015;28:1309-17.

421 [26] Debonnaire P, Leong DP, Witkowski TG, Al Amri I, Joyce E, Katsanos S, Schaliij

422 MJ, Bax JJ, Delgado V, Marsan NA. Left atrial function by two-dimensional speckle-  
 423 tracking echocardiography in patients with severe organic mitral regurgitation:  
 424 association with guidelines-based surgical indication and postoperative (long-term)  
 425 survival. *J Am Soc Echocardiogr* 2013;26:1053-62.

426 [27] Braunwald E, Awe WC. The syndrome of severe mitral regurgitation with normal  
 427 left atrial pressure. *Circulation* 1963;27:29-35.

428 [28] Verheule S, Wilson E, Everett T 4th, Shanbhag S, Golden C, Olgin J. Alterations  
 429 in atrial electrophysiology and tissue structure in a canine model of chronic atrial  
 430 dilatation due to mitral regurgitation. *Circulation* 2003;107:2615-22.

431 [29] Anné W, Willems R, Roskams T, Sergeant P, Herijgers P, Holemans P, Ector H,  
 432 Heidbüchel H. Matrix metalloproteinases and atrial remodeling in patients with mitral  
 433 valve disease and atrial fibrillation. *Cardiovasc Res* 2005;67:655-66.

434 [30] Zois NE, Tidholm A, Nägga KM, Moesgaard SG, Rasmussen CE, Falk T,  
 435 Häggström J, Pedersen HD, Åblad B, Nilsen HY, Olsen LH. Radial and longitudinal  
 436 strain and strain rate assessed by speckle-tracking echocardiography in dogs with  
 437 myxomatous mitral valve disease. *J Vet Intern Med* 2012;26:1309-19.

438 [31] Cameli M, Lisi M, Righini FM, Massoni A, Natali BM, Focardi M, Tacchini D, Geyer  
 439 A, Curci V, Di Tommaso C, Lisi G, Maccherini M, Chiavarelli M, Massetti M, Tanganelli

440 P, Mondillo S. Usefulness of atrial deformation analysis to predict left atrial fibrosis and  
 441 endocardial thickness in patients undergoing mitral valve operations for severe mitral  
 442 regurgitation secondary to mitral valve prolapse. *Am J Cardiol* 2013;111:595-601.

443 [32] Moustafa SE, Alharthi M, Kansal M, Deng Y, Chandrasekaran K, Mookadam F.  
 444 Global left atrial dysfunction and regional heterogeneity in primary chronic mitral  
 445 insufficiency. *Eur J Echocardiogr* 2011;12:384-93.

446 [33] Kokubu N, Yuda S, Tsuchihashi K, Hashimoto A, Nakata T, Miura T, Ura N, Nagao  
 447 K, Tsuzuki M, Wakabayashi C, Shimamoto K. Noninvasive assessment of left atrial  
 448 function by strain rate imaging in patients with hypertension: a possible beneficial effect  
 449 of renin-angiotensin system inhibition on left atrial function. *Hypertens Res*  
 450 2007;30:13-21.

451 [34] Wang Z, Tan H, Zhong M, Jiang G, Zhang Y, Zhang W. Strain rate imaging for  
 452 noninvasive functional quantification of the left atrium in hypertensive patients with  
 453 paroxysmal atrial fibrillation. *Cardiology* 2008;109:15-24.

454 [35] Yang CH, Liu HT, Lee HL, Lin FC, Chou CC. Left atrial booster-pump function as  
 455 a predictive parameter for atrial fibrillation in patients with severely dilated left atrium.  
 456 *Quant Imaging Med Surg* 2022;12:2523-34.

457 [36] Shang Z, Su D, Cong T, Sun Y, Liu Y, Chen N, Yang J. Assessment of left atrial

458 mechanical function and synchrony in paroxysmal atrial fibrillation with two-  
459 dimensional speckle tracking echocardiography. *Echocardiography* 2017;34:176-83.

460 [37] Dermlim A, Nakamura K, Morita T, Osuga T, Nisa K, Sasaoka K, Leela-Arporn R,  
461 Sasaki N, Ohta H, Takiguchi M. The Repeatability and Left Atrial Strain Analysis  
462 Obtained via Speckle Tracking Echocardiography in healthy Dogs. *J Vet Cardiol*  
463 2019;23:69-80.

464 [38] Leung JM, Bellows WH, Schiller NB. Impairment of left atrial function predicts post-  
465 operative atrial fibrillation after coronary artery bypass graft surgery. *Eur Heart J*  
466 2004;25:1836-44.

467 **Table**

468 Table 1. Clinical and echocardiographic characteristics of study population.

|                        |                  |
|------------------------|------------------|
| Age (years)            | 10 (9–12)        |
| Sex (male/female)      | 16/21            |
| Body weight (kg)       | 3.8 (3.1–5.8)    |
| Pulmonary oedema (y/n) | 23/14            |
| ACVIM class (B2/C/D)   | 14/14/9          |
| LA:Ao                  | 2.41 (2.00–2.80) |
| FS (%)                 | 51.1 (46.5–54.9) |
| LVIDDN                 | 2.03 (1.87–2.28) |
| LVIDSN                 | 0.98 (0.86–1.08) |
| E (cm/s)               | 122 (99–139)     |
| A (cm/s)               | 91 (67–104)      |
| E:A                    | 1.26 (1.08–1.66) |
| Ao (cm/s)              | 109 (94–131)     |
| PA (cm/s)              | 76 (66–92)       |
| PALS (%)               | 33.6 (23.6–38.9) |
| PACS (%)               | 13.4 (9.0–17.6)  |

469 A: peak velocity of late transmitral flow; ACVIM: American College of Veterinary Internal  
470 Medicine; Ao: peak velocity of left ventricular outflow tract; E: peak velocity of early diastolic  
471 transmitral flow; E:A: ratio of E to A; FS: fractional shortening; LA:Ao: left atrial to aortic root  
472 ratio; LVIDDN: left ventricular internal dimension at end-diastole normalized to body weight;  
473 LVIDSN: left ventricular internal dimension at end-systole normalized to body weight ; PA:  
474 peak velocity of right ventricular out flow tract; PACS: peak atrial contractile strain; PALS:  
475 peak atrial longitudinal strain.

476      Data are reported as median and lower and upper quartile.

477 Table 2. Changes in echocardiographic variables after MVP.

|           | baseline                      | early<br>postoperative        | one month                      | three months                   |
|-----------|-------------------------------|-------------------------------|--------------------------------|--------------------------------|
| LA:Ao     | 2.41 (2.00–2.80) <sup>a</sup> | 1.68 (1.54–1.92) <sup>b</sup> | 1.54 (1.45–1.72) <sup>bc</sup> | 1.46 (1.34–1.63) <sup>c</sup>  |
| FS (%)    | 51.1 (46.5–54.9) <sup>a</sup> | 31.3 (25.5–37.7) <sup>b</sup> | 31.8 (26.6–41.1) <sup>b</sup>  | 32.7 (28.2–40.5) <sup>b</sup>  |
| LVIDDN    | 2.03 (1.87–2.28) <sup>a</sup> | 1.60 (1.37–1.78) <sup>b</sup> | 1.61 (1.40–1.75) <sup>b</sup>  | 1.54 (1.43–1.65) <sup>b</sup>  |
| LVIDSN    | 0.98 (0.86–1.08)              | 1.09 (0.83–1.18)              | 1.00 (0.79–1.12)               | 1.03 (0.84–1.15)               |
| E (cm/s)  | 122 (99–139) <sup>a</sup>     | 82 (72–95) <sup>b</sup>       | 81 (71–88) <sup>b</sup>        | 73 (64–84) <sup>b</sup>        |
| A (cm/s)  | 91 (67–104) <sup>ab</sup>     | 85 (69–108) <sup>a</sup>      | 94 (82–108) <sup>ab</sup>      | 104 (89–119) <sup>b</sup>      |
| E:A       | 1.26 (1.08–1.70) <sup>a</sup> | 0.90 (0.80–1.17) <sup>b</sup> | 0.82 (0.75–0.92) <sup>b</sup>  | 0.73 (0.61–0.84) <sup>c</sup>  |
| Ao (cm/s) | 109 (94–131) <sup>ab</sup>    | 114 (102–138) <sup>a</sup>    | 114 (103–124) <sup>ab</sup>    | 101 (90–111) <sup>b</sup>      |
| PA (cm/s) | 76 (66–92) <sup>a</sup>       | 98 (81–118) <sup>b</sup>      | 96 (84–116) <sup>b</sup>       | 81 (70–95) <sup>ac</sup>       |
| PALS (%)  | 33.6 (23.6–38.9) <sup>a</sup> | 20.8 (15.5–25.9) <sup>b</sup> | 20.7 (18.2–27.5) <sup>b</sup>  | 24.2 (18.7–30.8) <sup>b</sup>  |
| PACS (%)  | 13.4 (9.0–17.6) <sup>ab</sup> | 10.5 (8.5–13.4) <sup>b</sup>  | 13.3 (10.3–16.8) <sup>b</sup>  | 16.4 (12.5–20.5) <sup>ac</sup> |

478 A: peak velocity of late transmitral flow; Ao: peak velocity of left ventricular outflow tract; E:  
479 peak velocity of early diastolic transmitral flow; E:A: ratio of E to A; FS: fractional shortening;  
480 LA:Ao: left atrial to aortic root ratio; LVIDDN: left ventricular internal dimension at end-  
481 diastole normalized to body weight; LVIDSN: left ventricular internal dimension at end-systole  
482 normalized to body weight ; MVP: mitral valvuloplasty; PA: peak velocity of right ventricular  
483 out flow tract; PACS; peak atrial contractile strain; PALS: peak atrial longitudinal strain.  
484 Data are reported as median and lower and upper quartile.  
485 Different letters indicate statistically significant differences according to the Steel-Dwass test  
486 ( $P < 0.05$ ).

487 Table 3. Correlation between baseline variables and LA size and function indices at three  
488 months.

|             | LA:Ao at three months |        | PALS at three months |        | PACS at three months |        |
|-------------|-----------------------|--------|----------------------|--------|----------------------|--------|
|             | P                     | $\rho$ | P                    | $\rho$ | P                    | $\rho$ |
| Age         | 0.602                 |        | 0.534                |        | 0.342                |        |
| Body Weight | 0.425                 |        | 0.265                |        | 0.220                |        |
| ACC         | 0.856                 |        | 0.784                |        | 0.538                |        |
| CBP         | 0.874                 |        | 0.958                |        | 0.988                |        |
| LA:Ao       | 0.002                 | 0.485  | 0.855                |        | 0.660                |        |
| FS          | 0.791                 |        | 0.776                |        | 0.886                |        |
| LVIDDN      | 0.073                 |        | 0.489                |        | 0.523                |        |
| LVIDSN      | 0.310                 |        | 0.859                |        | 0.784                |        |
| E           | 0.339                 |        | 0.576                |        | 0.512                |        |
| A           | 0.339                 |        | 0.341                |        | 0.086                |        |
| E:A         | 0.560                 |        | 0.803                |        | 0.493                |        |
| Ao          | 0.519                 |        | 0.998                |        | 0.807                |        |
| PA          | 0.823                 |        | 0.423                |        | 0.585                |        |
| PALS        | < 0.001               | -0.543 | 0.002                | 0.504  | < 0.001              | 0.563  |
| PACS        | < 0.001               | -0.546 | 0.001                | 0.514  | < 0.001              | 0.529  |

489 A: peak velocity of late transmitral flow; ACC: aortic cross clamp time; Ao: peak velocity of left  
490 ventricular outflow tract; CBP: cardiopulmonary bypass time; E: peak velocity of early  
491 diastolic transmitral flow; E:A: ratio of E to A; FS: fractional shortening; LA:Ao: left atrial to the  
492 aortic root ratio; LVIDDN: left ventricular internal dimension at end-diastole normalized to  
493 body weight; LVIDSN: left ventricular internal dimension at end-systole normalized to body  
494 weight ; PA: peak velocity of right ventricular out flow tract; PACS: peak atrial contraction

495 strain; PALS: peak atrial longitudinal strain.

496

497 Table 4 . Results of simple linear regression analyses for prediction of LA:Ao at three months  
 498 from preoperative left atrial size and function indices in 37 dogs.

| Variable           | R <sup>2</sup> | P       | Regression Equation                                            |
|--------------------|----------------|---------|----------------------------------------------------------------|
| preoperative LA:Ao | 0.26           | 0.001   | LA:Ao at three months = (0.2843 × preoperative LA:Ao) + 0.8156 |
| preoperative PALS  | 0.32           | < 0.001 | LA:Ao at three months = (-0.014 × preoperative PALS) + 1.954   |
| preoperative PACS  | 0.28           | < 0.001 | LA:Ao at three months = (-0.021 × preoperative PACS) + 1.799   |

499 LA:Ao: left atrial to the aortic root ratio; PACS: peak atrial contraction strain; PALS: peak  
 500 atrial longitudinal strain; R<sup>2</sup>: coefficient of determination

501

502 Table 5. Clinical and echocardiographic variable of LARR and non-LARR group at baseline.

|                                     | LARR (n=27)      | non-LARR (n=10)  | P     |
|-------------------------------------|------------------|------------------|-------|
| Age (years)                         | 10 (9–12)        | 12 (9–12)        | 0.476 |
| Sex (male/female)                   | 12/15            | 4/6              | 1.000 |
| Body weight (kg)                    | 3.7 (3.1–5.2)    | 4.5 (3.1–6.5)    | 0.451 |
| ACVIM class                         |                  |                  | 0.245 |
| B2                                  | 12 (44.4%)       | 2 (20%)          |       |
| C                                   | 9 (33.3%)        | 3 (30%)          |       |
| D                                   | 6 (22.2%)        | 5 (50%)          |       |
| Pulmonary oedema (yes/no)           | 15/12            | 8/2              | 0.260 |
| Medicine (Preoperative)             |                  |                  |       |
| ACE inhibitor                       | 20 (74.0%)       | 9 (90%)          | 0.404 |
| Pimobendan                          | 26 (96.3%)       | 10 (100%)        | 1.000 |
| Loop Diuretics                      | 20 (74%)         | 10 (100%)        | 0.155 |
| Spironolactone                      | 14 (51.8%)       | 6 (60%)          | 0.726 |
| Amlodipine                          | 18 (66.6%)       | 10 (100%)        | 0.079 |
| Medication (three months after MVP) |                  |                  |       |
| ACE inhibitor                       | 0                | 0                | 1.000 |
| Pimobendan                          | 0                | 2                | 0.068 |
| Loop diuretics                      | 0                | 0                | 1.000 |
| Spironolactone                      | 0                | 0                | 1.000 |
| Amlodipine                          | 0                | 0                | 1.000 |
| Surgery                             |                  |                  | 1.000 |
| ACC                                 | 106 (96–118)     | 111 (103–123)    | 0.374 |
| CPB                                 | 150 (140–161)    | 155 (136–176)    | 0.533 |
| Echocardiography                    |                  |                  |       |
| LA:Ao*                              | 2.32 (1.97–2.69) | 2.71 (2.50–3.05) | 0.008 |
| FS (%)                              | 50.9 (46.6–54.7) | 51.9 (45.8–59.2) | 0.694 |
| LVIDDN                              | 2.03 (1.82–2.17) | 2.23 (1.96–2.40) | 0.151 |
| LVIDSN                              | 0.97 (0.89–1.06) | 1.02 (0.80–1.18) | 0.707 |
| E (cm/s)                            | 123 (98–137)     | 119 (104–142)    | 0.837 |
| A (cm/s)                            | 93 (70–104)      | 91 (62–104)      | 0.701 |
| E:A                                 | 1.25 (1.08–1.70) | 1.28 (1.10–1.92) | 0.927 |
| Ao (cm/s)                           | 109 (93–132)     | 108 (97–134)     | 0.959 |

|           |                  |                  |       |
|-----------|------------------|------------------|-------|
| PA (cm/s) | 78 (66–91)       | 76 (65–105)      | 0.707 |
| PALS (%)* | 35.0 (30.8–40.7) | 24.0 (15.1–32.1) | 0.008 |
| PACS (%)* | 13.8 (11.1–19.6) | 7.8 (6.5–11.5)   | 0.002 |

503 A: peak velocity of late transmitral flow; ACC: aortic cross clamp time; ACE: angiotensin-  
504 converting enzyme; ACVIM: American College of Veterinary Medicine; Ao: peak velocity of  
505 left ventricular outflow tract; CBP: cardiopulmonary bypass time; E: peak velocity of early  
506 diastolic transmitral flow; E:A: ratio of E to A; FS: fractional shortening; LAAR: left atrial  
507 reverse remodelling; LA:Ao: left atrial to aortic root ratio; LVIDDN: left ventricular internal  
508 dimension at end-diastole normalized to body weight; LVIDSN: left ventricular internal  
509 dimension at end-systole normalized to body weight ; MVP: mitral valvuloplasty; PA: peak  
510 velocity of right ventricular out flow tract; PACS: peak atrial contraction strain; PALS: peak  
511 atrial longitudinal strain.

512 Data are reported as median and lower and upper quartile.

513 \*Value between LARR and non-LARR differed significantly ( $P < 0.05$ ).

514

515

516

517 Table 6. AUC and optimal diagnostic cutoffs between LARR and non-LARR.

|       | Cutoff | AUC   | Sensitivity | Specificity |
|-------|--------|-------|-------------|-------------|
| PACS  | 10.0   | 0.837 | 0.80        | 0.85        |
| PALS  | 30.8   | 0.789 | 0.80        | 0.74        |
| LA:Ao | 2.53   | 0.789 | 0.80        | 0.70        |

518 AUC: area under the receiver operating characteristic curve; LA:Ao: left atrial-to-aortic root  
519 ratio; LAAR: left atrial reverse remodelling; PACS: peak atrial contraction strain; PALS: peak  
520 atrial longitudinal strain.

521

522 Table 7. Binary logistic regression analysis of LARR three months after MVP

|          | Univariate analysis |             |       | Multivariate analysis |             |       |
|----------|---------------------|-------------|-------|-----------------------|-------------|-------|
| Variable | OR                  | 95%CI       | P     | OR                    | 95% CI      | P     |
| LA:Ao    | 15.824              | 2.190-200.8 | 0.014 |                       |             |       |
| PALS     | 0.877               | 0.794-0.967 | 0.009 |                       |             |       |
| PACS     | 0.740               | 0.585-0.935 | 0.012 | 0.760                 | 0.595-0.970 | 0.008 |

523 CI: confidence interval; LAAR: left atrial reverse remodelling; LA:Ao: left atrial to aortic root

524 ratio; MVP: mitral valvuloplasty; OR: odds ratio; PACS: peak atrial contraction strain; PALS:

525 peak atrial longitudinal strain.

526

527

## Figure legends


**Figure 1:** Left atrial strain curves from. Strain at the end of LA systole was established as the zero-reference value. The reservoir function of the left atrium is assessed with the first peak positive strain (PALS), and the contractile function is assessed with the second peak positive strain (PACS). PACS: peak atrial contraction strain; PALS: peak atrial longitudinal strain.




**Figure 2:** Time course change of LA:Ao (A), PALS (B), and PACS (C) at baseline (T0), in the early postoperative period (T1), and at one and three months (T2 and T3). Data are displayed as the median and lower and upper quartile (whiskers). Different letters indicate statistically significant differences according to Steel-Dwass test ( $P < 0.05$ ). LA:Ao: left atrial to aortic root ratio; PACS: peak atrial contraction strain; PALS: peak atrial longitudinal strain.




**Figure 3:** Scatter plots illustrating significant correlations between LA:Ao at three months after MVP and preoperative LA:Ao (A), PALS (B), PACS(C). LA:Ao: left atrial to aortic root ratio; MVP: mitral valvuloplasty; PACS: peak atrial contraction strain; PALS: peak atrial longitudinal strain.



**Figure 4:** Box plot graphics representing LA:Ao (A), PALS (B), PACS (C) in the LARR and non-LARR groups at baseline. Box plot indicates the median and lower and upper quartile; whiskers depict the range of distribution. Asterisk represents a significant difference according to Kruskal Wallis test ( $P < 0.05$ ). LA:Ao: left atrial to aortic root ratio; LARR: left

546 atrial reverse remodelling; PACS: peak atrial contraction strain; PALS: peak atrial longitudinal  
547 strain.







**A****B****C**